A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- Registration Number
- NCT00002330
- Lead Sponsor
- Roche Global Development
- Brief Summary
To compare the time to progression of Cytomegalovirus (CMV) retinitis among each of three doses of oral ganciclovir, as well as to intravenous therapy, when given as maintenance for 26 weeks. To compare the safety and tolerance among oral doses of ganciclovir at the study doses, as well as to intravenous therapy, when administered as maintenance for 26 weeks.
- Detailed Description
Patients who have received anti-CMV therapy with intravenous ganciclovir for at least 4 weeks that resulted in stable retinitis are randomized to receive one of three doses of oral ganciclovir or intravenous ganciclovir for 26 weeks of maintenance.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 280
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (36)
Univ of Alabama at Birmingham / AIDS Outpatient Clinic
🇺🇸Birmingham, Alabama, United States
McDowell Clinic
🇺🇸Phoenix, Arizona, United States
Dr Ken Fisher
🇺🇸Phoenix, Arizona, United States
Univ of Arizona / Health Science Ctr
🇺🇸Tucson, Arizona, United States
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States
AIDS Clinical Research Ctr / UCLA Med Ctr
🇺🇸Los Angeles, California, United States
UCSD Med Ctr / Pediatrics
🇺🇸San Diego, California, United States
Davies Med Ctr
🇺🇸San Francisco, California, United States
Mount Zion Med Ctr / UCSF
🇺🇸San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Scroll for more (26 remaining)Univ of Alabama at Birmingham / AIDS Outpatient Clinic🇺🇸Birmingham, Alabama, United States